The group's principal activity is to discover and develop drugs for the treatment of human viral and other infectious diseases. The group's current focus is on the treatment of infections caused by hepatitis b virus (hbv), hepatitis c virus (hcv) and human immunodeficiency virus (HIV). On Jul 27, 2004, the group completed its initial public offering.
